Spirea, a biotech company spun out from the University of Cambridge, is committed to delivering the next generation of antibody drug conjugate (ADC) therapeutics to revolutionise cancer treatment and improve the lives of patients.

Spirea will unlock a new generation of accessible, powerful and well-tolerated medicines for the treatment of a wide range of cancers.